Skip to main content
. 2014 Aug 13;3(6):1579–1594. doi: 10.1002/cam4.317

Figure 3.

Figure 3

Tumor growth curves showing greater growth inhibition by doublet and triplet regimen during active treatment period (Weeks 1–4) and greater delay in tumor regrowth in animals treated with the triplet when observed off treatment (Weeks 4–9). Inset showing different tumor regrowth kinetic between doublet (cisplatin and etoposide) and triplet treatment (veliparib [25 mg/kg], cisplatin [2.5 mg/kg i.p., weekly] and etoposide [20 mg/kg i.p., weekly]); P < 0.021.